Related Experiment Video

Updated: Mar 30, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.2K

Targeted Therapies in Triple-Negative Breast Cancer

Frederik Marmé1, Andreas Schneeweiss1

  • 1Universitäts-Frauenklinik, University of Heidelberg, Germany ; National Centre for Tumour Diseases, University of Heidelberg, Germany.

Breast Care (Basel, Switzerland)
|November 12, 2015
PubMed

Insights

Triple-negative breast cancer (TNBC) lacks targeted therapies, necessitating new approaches. This review covers emerging treatments like immune-checkpoint inhibitors and subtype-specific strategies for advanced TNBC.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Triple-negative breast cancer (TNBC) is a heterogeneous cancer lacking targeted therapies, with chemotherapy resistance and poor prognosis in metastatic stages.
  • Current treatments like bevacizumab show limited specific benefit for TNBC.

Purpose of the Study:

  • To review current clinical developments in targeted therapies for triple-negative breast cancer.
  • To discuss novel strategies and subtype-specific treatments for TNBC.

Main Methods:

  • Review of clinical developments in targeted approaches for TNBC.
  • Discussion of anti-angiogenic therapies, EGFR-targeted therapies, PARP inhibitors, platinum salts, and immune-checkpoint inhibitors.
  • Exploration of subtype-specific strategies, including anti-androgenic therapies for the luminal androgen receptor (LAR) subtype.

Main Results:

  • Emerging targeted therapies show promise for TNBC treatment.
  • Immune-checkpoint inhibitors have demonstrated initial promising results.
  • Subtype-specific therapies, such as anti-androgenic treatments for LAR TNBC, are under investigation.

Conclusions:

  • New targeted approaches are urgently needed for triple-negative breast cancer due to chemotherapy resistance and poor prognosis.
  • Immune-checkpoint inhibitors and subtype-specific therapies represent promising avenues for TNBC treatment.
  • Further research into targeted strategies is crucial for improving outcomes in advanced TNBC.
Keywords:
BevacizumabImmune-checkpoint inhibitorsPARP inhibitorsSubtypesTargeted therapyTriple-negative breast cancer

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K